Jocasta Neuroscience

Executive Summary

Jocasta Neuroscience is a Boston-based biotech founded in 2021, focusing on cognitive health through therapeutics targeting the Klotho protein. Klotho is an endogenous protein known to decline with age and linked to neuroprotection, memory, and resilience. The company's lead candidate, JN-0413, is a synthetic Klotho formulation designed to treat age-related cognitive decline. Jocasta aims to address the large unmet need in age-associated cognitive impairment, a condition lacking approved disease-modifying therapies. By restoring Klotho levels, JN-0413 could potentially improve synaptic function and slow cognitive deterioration. The company is at an early stage, with no disclosed funding rounds or clinical milestones. Its approach is scientifically compelling, given Klotho's role in aging, but it faces typical preclinical challenges including formulation stability and translational risk. Success would depend on demonstrating feasibility in animal models and advancing to human trials. The private status limits visibility into timelines, but the science offers a differentiated strategy versus amyloid-targeting Alzheimer's therapies.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Proof-of-Concept Data for JN-041340% success
• Q2 2027IND-Enabling Studies Initiation35% success
• TBDStrategic Partnership or Licensing Deal25% success